Skip to content
10-K

Annual Report

Neuphoria Therapeutics Inc. NEUP

0001193125-25-223338

← back to feed
Filed
Sep 29, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Sep 29, 2025 2.36M sh
Shares Diluted FY 2025 · Jun 30, 2025 1.62M sh
Shares Diluted restated FY 2025 · Jun 30, 2024 832.23K sh
Operating Cash Flow FY 2025 · Jun 30, 2025 $77.23K
Operating Cash Flow FY 2025 · Jun 30, 2024 −$14.68M
Cash And Equivalents FY 2025 · Jun 30, 2025 $14.21M
Cash And Equivalents FY 2025 · Jun 30, 2024 $12.61M
Stockholders Equity FY 2025 · Jun 30, 2025 $19M
Stockholders Equity FY 2025 · Jun 30, 2024 $17.49M
Stockholders Equity FY 2025 · Jun 30, 2023 $22.01M
Current Liabilities FY 2025 · Jun 30, 2025 $4.22M
Current Liabilities FY 2025 · Jun 30, 2024 $3.83M
Total Liabilities FY 2025 · Jun 30, 2025 $9.59M
Total Liabilities FY 2025 · Jun 30, 2024 $10.16M
Current Assets FY 2025 · Jun 30, 2025 $15.04M
Current Assets FY 2025 · Jun 30, 2024 $13.19M
Total Assets FY 2025 · Jun 30, 2025 $28.59M
Total Assets FY 2025 · Jun 30, 2024 $27.65M
Eps Diluted FY 2025 · Jun 30, 2025 −$0.23
Eps Diluted restated FY 2025 · Jun 30, 2024 −$18.62
Eps Basic FY 2025 · Jun 30, 2025 −$0.23
Eps Basic restated FY 2025 · Jun 30, 2024 −$18.62
Sga Expense FY 2025 · Jun 30, 2025 $7.77M
Sga Expense FY 2025 · Jun 30, 2024 $8.47M
Rd Expense FY 2025 · Jun 30, 2025 $9.01M
Rd Expense FY 2025 · Jun 30, 2024 $9.42M
Net Income FY 2025 · Jun 30, 2025 −$369.63K
Net Income FY 2025 · Jun 30, 2024 −$15.49M
Operating Income FY 2025 · Jun 30, 2025 −$1.13M
Operating Income FY 2025 · Jun 30, 2024 −$17.89M
Revenue FY 2025 · Jun 30, 2025 $15.65M